Ultimately our results from a large dataset of patients with metastatic disease do not support loss of PTEN expression based on CNA as a prognostic marker in the overall population or any subgroups based on KRAS or BRAF mutation status. This evidence concerns the gene BRAF and metastatic neoplasm.